Why the study?
Does cilazapril or bosentan reduce blood pressure and vascular hypertrophy in spontaneously hypertensive rats treated with L-NAME?
Does cilazapril or bosentan reduce blood pressure and vascular hypertrophy in spontaneously hypertensive rats treated with L-NAME?
In a rat model of malignant hypertension induced by L-NAME, ACE inhibition but not endothelin antagonism lowered blood pressure and reduced vascular hypertrophy, suggesting a key role for the renin-angiotensin system.
Answers are grounded in this paper and cite their sources.
ACE inhibition but not endothelin antagonism attenuates vascular hypertrophy in L-NAME rats; leaves open clinical relevance in human malignant hypertension.
Inhibition of nitric oxide synthase by L-arginine analogues such as N omega-nitro-L-arginine methyl ester (L-NAME) in spontaneously hypertensive rats (SHR) is associated with malignant hypertension and enhanced expression of the endothelin-1 gene in some blood vessels. In this study, SHR treated chronically with L-NAME (SHR-L-NAME) were given the angiotensin I-converting enzyme inhibitor cilazapril or the endothelin-A/endothelin-B receptor antagonist bosentan for 3 weeks. Systolic pressure was lowered slightly by cilazapril (213 +/- 2 versus 229 +/- 2 mm Hg in untreated SHR-L-NAME, P < .01) but was not significantly lowered by bosentan (223 +/- 2 mm Hg). Hypertrophy of aorta and small arteries (coronary, renal, mesenteric, and femoral) was decreased by cilazapril treatment and unaffected by bosentan. Expression of the endothelin-1 gene was evaluated in SHR-L-NAME by in situ hybridization histochemistry, which showed that endothelin-1 expression was enhanced in the endothelium of aorta but not in small mesenteric arteries in these rats. The absence of enhancement of endothelin-1 gene expression in small arteries may account for the absence of increased severity of hypertrophy of small vessels in SHR-L-NAME and may be a mechanism whereby L-NAME inhibits cardiovascular growth. These results suggest that in the absence of enhanced small-artery endothelin-1 expression, endothelin antagonism does not lower blood pressure. The blood pressure-lowering effect of angiotensin I-converting enzyme inhibition suggests a role for the renin-angiotensin system in the malignant form of hypertension that develops in SHR treated with L-NAME.
No takes yet. Share an insight, caveat, or question.
Li et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: